Clinical evaluation of combined immunosuppressive therapy for psoriasis
V. A. Okhlopkov, O. V. Pravdina, D. S. Melnichenko, E. I. Poleschuk, T. V. Repina · 2017 · Clinical Dermatology and Venereology. 2017;16(3):64–69
Study data at a glance
- Participants or experimental model
- 48 patients allocated to three groups of 16; five pregnant patients followed separately
- Reported results
- This small study compares narrow-band UVB, Thymodepressin and their combination over 21 days, reporting a stronger response with combined care.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Only 48 participants belong to the randomized comparison; the five pregnant patients are a separate nonrandomized cohort.
- Open-label comparison, small groups and short follow-up limit efficacy and safety conclusions.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Original publisher text checked for allocation, separate pregnancy cohort and short-term findings.
Recorded source-check date: 2026-11-05. This date does not imply a completed systematic review.
Citation and original source
Original source: V. A. Okhlopkov, O. V. Pravdina, D. S. Melnichenko, E. I. Poleschuk, T. V. Repina. Clinical evaluation of combined immunosuppressive therapy for psoriasis Clinical Dermatology and Venereology. 2017;16(3):64–69 2017.
Molekul research summary: https://molekul.io/research/auto-thymodepressin-psoriasis-2017. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry